Salute e Benessere
Orphalan becomes the first European company to enter in China's Wilson Disease market
This launch is made possible through a , a leading pharmaceutical distributor in China and a subsidiary of , one of the country's largest healthcare conglomerates. Together, Orphalan and SPH Kyuan Trade will work to to this critical treatment.
Wilson's disease is a rare, that affects the body's ability to eliminate excess copper. Without proper treatment, it can lead to severe neurological and hepatic complications. While penicillamine has been a standard therapy for years, many patients cannot tolerate it, leaving them with —until now.
Orphalan's " Ke Pei Ou " (科佩欧®), is the . Already available in more than 20 countries under the names (EU, UK, Saudi Arabia , Switzerland , Colombia , New Zealand ) and (US), this treatment should become a life changing therapy for thousands of patients in China .
Now, under the name " , it is , bringing new hope to who previously had no alternative.
Recognizing the strategic importance of China in its global mission, Orphalan has and appointed as . Backed by a , she will oversee efforts to:
This milestone is part of Orphalan's . By successfully entering the Chinese pharmaceutical market, the company is solidifying its role as a .
Dr. Naseem Amin , CEO of Orphalan, underlined the significance of this achievement:
As Orphalan continues to push the boundaries of , it remains .
With now available in China , Orphalan is setting a new standard for .
Orphalan is an international orphan drug focused pharmaceutical company headquartered in Paris . Founded in 2011, the Company's purpose is to develop and deliver innovative therapies for people living with rare and debilitating diseases. Our commitment is to work collaboratively with the rare disease and scientific communities to develop evidence-based treatments in areas of unmet need. Our trientine tetrahydrochloride product has been approved for the treatment of Wilson disease and is available in more than 20 countries, branded as Cuprior® in EU, the UK, Saudi Arabia , Switzerland , Columbia and New Zealand , as Cuvrior® in the United States , and as Ke Pei Ou " in China . For more information visit www.orphalan.com and follow us on Linkedin: Orphalan.
Géraldine van den Broek, Head of Corporate & BD
Tel: +33 (0)1 42 49 82 64
info@orphalan.com
Marie-Charlotte Potet
06 70 91 25 23
mc.potet@bcadvisory.fr
Logo - https://mma.prnewswire.com/media/2636119/Orphalan_logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/orphalan-becomes-the-first-european-company-to-enter-in-chinas-wilson-disease-market-302395036.html